2-18fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: A retrospective validation of the sempet trial

Annals of Oncology

Volumn 23, Issue 1, 2012, Pages 59-64

  Bachner, M ^a   Loriot, Y ^b   Gross goupil, M ^b   Zucali, P A ^c   Horwich, A ^d   Germa lluch, J R ^e   Kollmannsberger, C ^f   Stoiber, F ^g   Flechon A ^h   Oechsle, K ⁱ   Gillessen, S ^j   Oldenburg, J ^k   Cohn cedermark, G ^l   Daugaard, G ^m   Morelli, F ⁿ   Sella, A ^o   Harland, S ^p   Kerst, M ^q   Gampe, J ^r   Dittrich, C ^a   Fizazi, K ^b   De Santis, M ^a   more..

^a LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^d ROYAL MARSDEN HOSPITAL   (United Kingdom)

^e CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^f BRITISH COLUMBIA CANCER AGENCY   (Canada)

^g Krankenhaus der Barmherzigen Schwestern Wien Betriebsgesellschaft   (Austria)

^h CENTRE LÉON BÉRARD   (France)

ⁱ UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^j CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^k OSLO UNIVERSITY HOSPITAL   (Norway)

^l KAROLINSKA INSTITUTE   (Sweden)

^m International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

ⁿ CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^o ASSAF HAROFEH MEDICAL CENTER   (Israel)

^p UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^q NETHERLANDS CANCER INSTITUTE   (Netherlands)

^r MAX PLANCK INSTITUTE FOR DEMOGRAPHIC RESEARCH   (Germany)

more..

Author keywords

Chemotherapy; FDG PET; Follow up; Postchemotherapy residual lesions; Seminoma; Testicular cancer

Indexed keywords

FLUORODEOXYGLUCOSE F 18; PLATINUM DERIVATIVE; 2 FLUORO 2 DEOXYGLUCOSE 6 PHOSPHATE; 2-FLUORO-2-DEOXYGLUCOSE-6-PHOSPHATE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; GLUCOSE 6 PHOSPHATE; RADIOPHARMACEUTICAL AGENT;

ARTICLE; CANCER CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MINIMAL RESIDUAL DISEASE; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; POSTCHEMOTHERAPY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEMINOMA; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; VALIDATION PROCESS; SCINTISCANNING; TESTIS TUMOR; VALIDATION STUDY;

GLUCOSE-6-PHOSPHATE; HUMANS; MALE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SEMINOMA; SENSITIVITY AND SPECIFICITY; TESTICULAR NEOPLASMS;

EID: 84855175352     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr052     Document Type: Article

References (69)

1. Peckham MJ, Horwich A, Hendry WF. Advanced seminoma: treatment with cisplatinum-based combination chemotherapy or carboplatin (JM8). Br J Cancer 1985; 52: 7-13.
2. Fossa SD, Borge L, Aass N et al. The treatment of advanced metastatic seminoma: experience in 55 cases. J Clin Oncol 1987; 5: 1071-1077.
3. Motzer R, Bosl G, Heelan R et al. Residual mass: an indication for further therapy in patients with advanced seminoma following systemic chemotherapy. J Clin Oncol 1987; 5: 1064-1070.
4. Puc HS, Heelan R, Mazumdar M et al. Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. J Clin Oncol 1996; 14: 454-460.
5. Duchesne GM, Stenning SP, Aass N et al. Radiotherapy after chemotherapy for metastatic seminoma-a diminishing role. MRC Testicular Tumour Working Party. Eur J Cancer 1997; 33: 829-835.
6. Fossa SD, Oliver RT, Stenning SP et al. Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy. Eur J Cancer 1997; 33: 1380-1387.
7. Herr HW, Sheinfeld J, Puc HS et al. Surgery for a post-chemotherapy residual mass in seminoma. J Urol 1997; 157: 860-862.
8. Horwich A, Paluchowska B, Norman A et al. Residual mass following chemotherapy of seminoma. Ann Oncol 1997; 8: 37-40.
9. Horwich A, Oliver RT, Wilkinson PM et al. A medical research council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma. MRC Testicular Tumour Working Party. Br J Cancer 2000; 83: 1623-1629.
10. Stanton GF, Bosl GJ, Whitmore WF Jr et al. VAB-6 as initial treatment of patients with advanced seminoma. J Clin Oncol 1985; 3: 336-339.
11. Ravi R, Ong J, Oliver RT et al. The management of residual masses after chemotherapy in metastatic seminoma. BJU Int 1999; 83: 649-653.
12. Ganjoo KN, Chan RJ, Sharma M, Einhorn LH. Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma. J Clin Oncol 1999; 17: 3457-3460.
13. De Santis M, Bokemeyer C, Becherer A et al. Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma. J Clin Oncol 2001; 19: 3740-3744.
14. De Santis M, Becherer A, Bokemeyer C et al. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol 2004; 22: 1034-1039.
15. Heidenreich A, Thuer D, Polyakov S. Postchemotherapy retroperitoneal lymph node dissection in advanced germ cell tumours of the testis. Eur Urol 2008; 53: 260-272.
16. Friedman EL, Garnick MB, Stomper PC et al. Therapeutic guidelines and results in advanced seminoma. J Clin Oncol 1985; 3: 1325-1332.
17. Schultz SM, Einhorn LH, Conces DJ Jr et al. Management of postchemotherapy residual mass in patients with advanced seminoma: Indiana University experience. J Clin Oncol 1989; 7: 1497-1503.
18. Coogan CL, Hejase MJ, Wahle GR et al. Nerve sparing post-chemotherapy retroperitoneal lymph node dissection for advanced testicular cancer. J Urol 1996; 156: 1656-1658.
19. Fléchon A, Bompas E, Biron P, Droz JP. Management of post-chemotherapy residual masses in advanced seminoma. J Urol 2002; 168: 1975-1979.
20. Mosharafa AA, Foster RS, Leibovich BC et al. Is post-chemotherapy resection of seminomatous elements associated with higher acute morbidity? J Urol 2003; 169: 2126-2128.
21. Mosharafa AA, Foster RS, Koch MO et al. Complications of post-chemotherapy retroperitoneal lymph node dissection for testis cancer. J Urol 2004; 171: 1839-1841.
22. Hinz S, Schrader M, Kempkensteffen C et al. The role of positron emission tomography in the evaluation of residual masses after chemotherapy for advanced stage seminoma. J Urol 2008; 179: 936-940; discussion 940.
23. Johns Putra L, Lawrentschuk N, Ballok Z et al. 18F-fluorodeoxyglucose positron emission tomography in evaluation of germ cell tumor after chemotherapy. Urology 2004; 64: 1202-1207.
24. Lewis DA, Tann M, Kesler K et al. Positron emission tomography scans in postchemotherapy seminoma patients with residual masses: a retrospective review from Indiana University Hospital. J Clin Oncol 2006; 24: e54-e55.
25. Schmoll HJ, Souchon R, Krege S et al. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 2004; 15: 1377-1399.
26. Krege S, Beyer J, Souchon R et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol 2008; 53: 497-513.
27. Albers P, Albrecht W, Algaba F et al. Guidelines on testicular cancer. European Association of Urology (EAU) 2009; www.uroweb.org/fileadmin/tx_eauguidelines/2009/Full/Testis_Cancer.pdf (8 March 2011, date last accessed).
28. Schmoll HJ, Jordan K, Huddart R et al. Testicular seminoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 (Suppl 4): 83-88.
29. Motzer RJ, Agarwal N, Beard C et al. NCCN clinical practice guidelines in oncology: testicular cancer. J Natl Compr Canc Netw 2009; 7: 672-693.
30. Keyes JW Jr. SUV: standard uptake or silly useless value? J Nucl Med 1995; 36: 1836-1839.
31. Wu HM, Hoh CK, Huang SC et al. Quantification of serial tumor glucose metabolism. J Nucl Med 1996; 37: 506-513.
32. Cremerius U, Effert PJ, Adam G et al. FDG PET for detection and therapy control of metastatic germ cell tumor. J Nucl Med 1998; 39: 815-822.
33. Shahidi M, Norman AR, Dearnaley DP et al. Late recurrence in 1263 men with testicular germ cell tumors. Multivariate analysis of risk factors and implications for management. Cancer 2002; 95: 520-530.
34. Chung PW, Gospodarowicz MK, Panzarella T et al. Stage II testicular seminoma: patterns of recurrence and outcome of treatment. Eur Urol 2004; 45: 754-759; discussion 759-760.
35. Kubota R, Kubota K, Yamada S et al. Microautoradiographic study for the differentiation of intratumoral macrophages, granulation tissues and cancer cells by the dynamics of fluorine-18-fluorodeoxyglucose uptake. J Nucl Med 1994; 35: 104-112.
36. Wilson CB, Young HE, Ott RJ et al. Imaging metastatic testicular germ cell tumours with 18FDG positron emission tomography: prospects for detection and management. Eur J Nucl Med 1995; 22: 508-513.
37. Strauss LG. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med 1996; 23: 1409-1415.
38. Nuutinen JM, Leskinen S, Elomaa I et al. Detection of residual tumours in postchemotherapy testicular cancer by FDG-PET. Eur J Cancer 1997; 33: 1234-1241.
39. Eary JF. Nuclear medicine in cancer diagnosis. Lancet 1999; 354: 853-857.
40. Hain SF, O'Doherty MJ, Timothy AR et al. Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse. Br J Cancer 2000; 83: 863-869.
41. Cohade C, Wahl RL. PET scanning and measuring the impact of treatment. Cancer J 2002; 8: 119-134.
42. Karapetis CS, Strickland AH, Yip D et al. Use of fluorodeoxyglucose positron emission tomography scans in patients with advanced germ cell tumour following chemotherapy: single-centre experience with long-term follow up. Intern Med J 2003; 33: 427-435.
43. Spaepen K, Stroobants S, Dupont P et al. [(18)F]FDG PET monitoring of tumour response to chemotherapy: does [(18)F]FDG uptake correlate with the viable tumour cell fraction? Eur J Nucl Med Mol Imaging 2003; 30: 682-688.
44. Stroobants S, Goeminne J, Seegers M et al. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 2003; 39: 2012-2020.
45. Juweid ME, Stroobants S, Hoekstra OS et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25: 571-578.
46. Haberkorn U, Strauss LG, Dimitrakopoulou A et al. PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy. J Nucl Med 1991; 32: 1485-1490.
47. Brudin LH, Valind SO, Rhodes CG et al. Fluorine-18 deoxyglucose uptake in sarcoidosis measured with positron emission tomography. Eur J Nucl Med 1994; 21: 297-305.
48. Maszelin P, Lumbroso J, Theodore C et al. [Fluorodeoxyglucose (FDO) positron emission tomography (PET) in testicular germ cell tumors in adults: preliminary French clinical evaluation, development of the technique and its clinical applications]. Prog Urol 2000; 10: 1190-1199.
49. Sanchez D, Zudaire JJ, Fernandez JM et al. 18F-fluoro-2-deoxyglucose-positron emission tomography in the evaluation of nonseminomatous germ cell tumours at relapse. BJU Int 2002; 89: 912-916.
50. Spermon JR, De Geus-Oei LF, Kiemeney LA et al. The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours. BJU Int 2002; 89: 549-556.
51. Spaepen K, Stroobants S, Verhoef G, Mortelmans L. Positron emission tomography with [(18)F]FDG for therapy response monitoring in lymphoma patients. Eur J Nucl Med Mol Imaging 2003; 30 (Suppl 1): S97-S105.
52. De Giorgi U, Pupi A, Fiorentini G et al. FDG-PET in the management of germ cell tumor. Ann Oncol 2005; 16 (Suppl 4): iv90-iv94.
53. Chowdhury FU, Sheerin F, Bradley KM, Gleeson FV. Sarcoid-like reaction to malignancy on whole-body integrated (18)F-FDG PET/CT: prevalence and disease pattern. Clin Radiol 2009; 64: 675-681.
54. Antoch G, Saoudi N, Kuehl H et al. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol 2004; 22: 4357-4368.
55. Steele RJ, Brown M, Eremin O. Characterisation of macrophages infiltrating human mammary carcinomas. Br J Cancer 1985; 51: 135-138.
56. Kubota R, Yamada S, Kubota K et al. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992; 33: 1972-1980.
57. Kubota R, Kubota K, Yamada S et al. Active and passive mechanisms of [fluorine-18] fluorodeoxyglucose uptake by proliferating and prenecrotic cancer cells in vivo: a microautoradiographic study. J Nucl Med 1994; 35: 1067-1075.
58. Minn H, Kangas L, Kellokumpu-Lehtinen P et al. Uptake of 2-fluoro-2-deoxy-D-[U-14C]-glucose during chemotherapy in murine Lewis lung tumor. Int J Rad Appl Instrum B 1992; 19: 55-63.
59. Haberkorn U, Reinhardt M, Strauss LG et al. Metabolic design of combination therapy: use of enhanced fluorodeoxyglucose uptake caused by chemotherapy. J Nucl Med 1992; 33: 1981-1987.
60. Findlay M, Young H, Cunningham D et al. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol 1996; 14: 700-708.
61. Hoekstra OS, Ossenkoppele GJ, Golding R et al. Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy. J Nucl Med 1993; 34: 1706-1710.
62. Muller-Mattheis V, Reinhardt M, Gerharz CD et al. [Positron emission tomography with [18 F]-2-fluoro-2-deoxy-D-glucose (18FDG-PET) in diagnosis of retroperitoneal lymph node metastases of testicular tumors]. Urologe A 1998; 37: 609-620.
63. Albers P, Bender H, Yilmaz H et al. Positron emission tomography in the clinical staging of patients with stage I and II testicular germ cell tumors. Urology 1999; 53: 808-811.
64. Cremerius U, Wildberger JE, Borchers H et al. Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer? -Results of a study in 50 patients. Urology 1999; 54: 900-904.
65. Hofer C, Kubler H, Hartung R et al. Diagnosis and monitoring of urological tumors using positron emission tomography. Eur Urol 2001; 40: 481-487.
66. Tsatalpas P, Beuthien-Baumann B, Kropp J et al. Diagnostic value of 18F-FDG positron emission tomography for detection and treatment control of malignant germ cell tumors. Urol Int 2002; 68: 157-163.
67. Hain SF. Positron emission tomography in uro-oncology. Cancer Imaging 2005; 5: 1-7.
68. Van den Abbeele AD. The lessons of GIST-PET and PET/CT: a new paradigm for imaging. Oncologist 2008; 13 (Suppl 2): 8-13.
69. Basu S. PET and PET/CT in gastrointestinal stromal tumours: the unanswered questions and the potential newer applications. Eur J Nucl Med Mol Imaging 2010; 37: 1255-1258.